

# Nicholas Manolios

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5518615/publications.pdf>

Version: 2024-02-01

131  
papers

2,934  
citations

186209

28  
h-index

189801

50  
g-index

133  
all docs

133  
docs citations

133  
times ranked

3237  
citing authors

#	ARTICLE	IF	CITATIONS
1	The disproportionately large contribution of the Māori and Pacific Islander community to the healthcare burden of gout in Western Sydney. <i>Internal Medicine Journal</i> , 2023, 53, 1450-1457.	0.5	2
2	Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy. <i>Internal Medicine Journal</i> , 2022, 52, 818-827.	0.5	3
3	<scp>Epsteinâ€Barr</scp> virus-related lymphoma in rheumatoid arthritis: implications for long-term usage of immunosuppressive drugs and review of the literature. <i>Internal Medicine Journal</i> , 2022, 52, 1717-1723.	0.5	3
4	The diagnostic accuracy of temporal artery ultrasound and temporal artery biopsy in giant cell arteritis: A single center Australian experience over 10 years. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 447-453.	0.9	4
5	<sup>99m</sup> Tc-labelled glucosamine in the assessment of systemic sclerosis inflammatory lung disease: a novel inexpensive investigative tool with predictive value. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1157-1166.	1.2	2
6	Correspondence on "Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?" <sup>TM</sup> . <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2020-219694.	0.5	2
7	Leptomeningitis in rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2021, 8, 48-50.	1.3	6
8	Arthritis in the hands of saints. <i>Rheumatology International</i> , 2021, 41, 1705-1706.	1.5	1
9	An enquiry into the crippling gout affecting Pacific Islander and Māori men in Western Sydney. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1394-1401.	0.9	3
10	The ha(r)sh drug interactions in rheumatology. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1258-1260.	0.9	0
11	The utility of dual energy computed tomography in the management of axial gout: case reports and literature review. <i>BMC Rheumatology</i> , 2020, 4, 22.	0.6	7
12	The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia. <i>European Journal of Rheumatology</i> , 2020, 7, S91-S93.	1.3	16
13	IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. <i>Scientific Reports</i> , 2019, 9, 14834.	1.6	16
14	AB0074â€¦INTERRELATIONSHIP BETWEEN NICOTINIC ACETYLCHOLINE RECEPTOR AND CYTOKINE PRODUCTION NOTED FOLLOWING T-CELL ANTIGEN RECOGNITION AND ACTIVATION. , 2019, , .		0
15	Checkpoint inhibitors and arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e58-e58.	0.5	4
16	Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1915-1923.	0.9	15
17	Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2018, 70, 39-52.	1.5	95
18	Acute arthritis: predictive factors and current practice in the approach to diagnosis and management across two hospitals in Sydney. <i>Internal Medicine Journal</i> , 2018, 48, 1087-1095.	0.5	8

#	ARTICLE	IF	CITATIONS
19	Coturnism. Internal Medicine Journal, 2018, 48, 1009-1009.	0.5	1
20	Endocannabinoids in arthritis: current views and perspective. International Journal of Rheumatic Diseases, 2017, 20, 789-797.	0.9	13
21	The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. European Journal of Rheumatology, 2017, 4, 210-218.	1.3	87
22	Lupus Means Sacrifices: Perspectives of Adolescents and Young Adults With Systemic Lupus Erythematosus. Arthritis Care and Research, 2016, 68, 828-837.	1.5	53
23	Evaluating disease activity in patients with ankylosing spondylitis and rheumatoid arthritis using 99mTc-glucosamine. European Journal of Rheumatology, 2016, 3, 65-72.	1.3	9
24	The motherhood choices decision aid for women with rheumatoid arthritis increases knowledge and reduces decisional conflict: a randomized controlled trial. BMC Musculoskeletal Disorders, 2015, 16, 260.	0.8	30
25	Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma. Journal of Immunotherapy, 2015, 38, 37-39.	1.2	112
26	Acute gross painless transudative ascites in a patient with lupus. BMJ Case Reports, 2014, 2014, bcr2013201503-bcr2013201503.	0.2	1
27	The role of 99mTc-labelled glucosamine (99mTc-ECDG) in the evaluation of rheumatic joint disease. Nuclear Medicine Communications, 2014, 35, 655-665.	0.5	7
28	Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis. Clinical Immunology, 2014, 151, 43-54.	1.4	50
29	Cyclization enhances function of linear anti-arthritis peptides. Clinical Immunology, 2014, 150, 121-133.	1.4	9
30	Novel T-cell inhibiting peptides delay the onset of Type 1 diabetes in non-obese diabetic mice. Diabetes and Metabolism, 2014, 40, 229-234.	1.4	3
31	Engraftment of plasma membrane vesicles into liposomes: A new method for designing of liposome-based vaccines. Iranian Journal of Basic Medical Sciences, 2014, 17, 772-8.	1.0	1
32	Navigating Motherhood Choices in the context of Rheumatoid Arthritis: Women's Stories. Musculoskeletal Care, 2013, 11, 73-82.	0.6	26
33	Effectiveness of moving on: an Australian designed generic self-management program for people with a chronic illness. BMC Health Services Research, 2013, 13, 90.	0.9	11
34	Alanine Scan of an Immunosuppressive Peptide (CP): Analysis of Structure-Function Relationships. Chemical Biology and Drug Design, 2013, 81, 167-174.	1.5	6
35	Cauda Equina Syndrome in Ankylosing Spondylitis. Journal of Clinical Rheumatology, 2013, 19, 163.	0.5	1
36	A preliminary investigation of cognitive function in rheumatoid arthritis patients on long-term methotrexate treatment. Journal of Health Psychology, 2013, 18, 1353-1359.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Assessing Cognitive Function in Rheumatoid Arthritis: Comment on the Article by Shin et al. Arthritis Care and Research, 2013, 65, 1390-1390.	1.5	1
38	Failure of anti-TNF therapy to reactivate previously septic prosthetic joints. BMJ Case Reports, 2013, 2013, bcr2013009827-bcr2013009827.	0.2	2
39	No more excuses: fracture liaison services work and are cost-effective. Medical Journal of Australia, 2012, 196, 384-384.	0.8	5
40	New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Internal Medicine Journal, 2012, 42, 89-94.	0.5	83
41	Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis. Peptides, 2011, 32, 1567-1574.	1.2	35
42	<sup>99m</sup> Tc-technetium labeling of antiarthritic peptides to evaluate homing and biodistribution at inflamed joints. Nuclear Medicine and Biology, 2011, 38, 751-756.	0.3	6
43	Antitopoisomerase antibody positivity predates nailfold capillaroscopy abnormalities in scleroderma. Postulated classification of "prescleroderma"™. Internal Medicine Journal, 2011, 41, 197-199.	0.5	4
44	NMR study of the structure and self-association of core peptide in aqueous solution and DPC micelles. Biopolymers, 2011, 96, 177-180.	1.2	6
45	Anti-Arthritic Effects of Immunomodulatory Peptide Injected in Joints. Current Drug Delivery, 2011, 8, 600-606.	0.8	1
46	Biopsy Diagnosis of Early Myositis Ossificans Without Radiologic Evidence of Calcification. Journal of Clinical Rheumatology, 2010, 16, 385-387.	0.5	8
47	Pseudohypercalcaemia in mixed cryoglobulinaemia (IgM <sup>κ</sup> /polyclonal IgG): a rare complication of Sjögren's syndrome. Clinical Rheumatology, 2010, 29, 439-441.	1.0	1
48	Clinical images: Calcifying pseudoneoplasm of the neuraxis. Arthritis and Rheumatism, 2010, 62, 704-704.	6.7	17
49	AUTOIMMUNITY AND THE MUSCULOSKELETAL SYSTEM. , 2010, , 123-135.		0
50	T-cell antigen receptor (TCR) transmembrane peptides. Cell Adhesion and Migration, 2010, 4, 273-283.	1.1	8
51	Gene therapy in diabetes. Self/nonsel, 2010, 1, 165-175.	2.0	34
52	The Potential of Liposomal Drug Delivery for the Treatment of Inflammatory Arthritis. Seminars in Arthritis and Rheumatism, 2009, 39, 182-196.	1.6	54
53	Psoriatic arthritis and chronic lymphoedema: treatment efficacy by adalimumab. Clinical Rheumatology, 2009, 28, 1349-1350.	1.0	10
54	Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice. Internal Medicine Journal, 2009, 39, 228-236.	0.5	27

#	ARTICLE	IF	CITATIONS
55	Kinetic and conformational properties of a novel T-cell antigen receptor transmembrane peptide in model membranes. <i>Journal of Peptide Science</i> , 2008, 14, 714-724.	0.8	25
56	Familial scleroderma: nature, nurture or both?. <i>Internal Medicine Journal</i> , 2008, 38, 235-242.	0.5	3
57	Autologous stem cell transplantation in diffuse scleroderma: impact on hand structure and function. <i>Internal Medicine Journal</i> , 2008, 38, 080311021334281-???	0.5	8
58	P2X <sub>7</sub> gene polymorphisms do not appear to be a susceptibility gene locus in sporadic cases of systemic lupus erythematosus. <i>Tissue Antigens</i> , 2008, 72, 487-490.	1.0	14
59	Hypothesis: TCR signal transduction – A novel tri-modular signaling system. <i>Molecular Immunology</i> , 2008, 45, 876-880.	1.0	4
60	Evidence-based recommendations for the monitoring and treatment of ankylosing spondylitis: results from the Australian 3E initiative in rheumatology. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 45-49.	0.9	0
61	Evidence-based recommendations for the diagnosis of ankylosing spondylitis: results from the Australian 3E initiative in rheumatology. <i>Medical Journal of Australia</i> , 2008, 188, 235-237.	0.8	8
62	Therapeutic Application of Transmembrane T and Natural Killer Cell Receptor Peptides. <i>Advances in Experimental Medicine and Biology</i> , 2008, 640, 208-219.	0.8	11
63	T-Cell Antigen Receptor Assembly and Cell Surface Expression Is Not Affected by Treatment with T-Cell Antigen Receptor-Alpha Chain Transmembrane Peptide. <i>Protein and Peptide Letters</i> , 2007, 14, 299-303.	0.4	9
64	Peptide-based therapies for arthritis. <i>Future Rheumatology</i> , 2007, 2, 287-296.	0.2	1
65	Reconstructive Hand Surgery for Scleroderma Joint Contractures. <i>Journal of Hand Surgery</i> , 2007, 32, 1107-1112.	0.7	14
66	Novel cationic lipophilic peptides for oligodeoxynucleotide delivery. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 4091-4097.	1.4	7
67	The mode of anti-arthritis peptide delivery impacts on the severity and outcome of adjuvant induced arthritis. <i>APLAR Journal of Rheumatology</i> , 2007, 10, 198-203.	0.2	7
68	Magnetic resonance imaging in LÃ¶fgren's syndrome: demonstration of peri-arthritis. <i>Clinical Rheumatology</i> , 2007, 26, 572-575.	1.0	21
69	Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma. <i>Clinical Rheumatology</i> , 2007, 26, 1136-1141.	1.0	11
70	Hypercarotenaemia. <i>Internal Medicine Journal</i> , 2006, 36, 534-534.	0.5	0
71	Resolution of skin fibrosis and joint contractures in aggressive diffuse systemic sclerosis using autologous stem cell transplantation. <i>APLAR Journal of Rheumatology</i> , 2006, 9, 298-301.	0.2	0
72	Discrepancy in CD3-Transmembrane Peptide Activity between In Vitro and In Vivo T-Cell Inhibition. <i>Scandinavian Journal of Immunology</i> , 2006, 64, 388-391.	1.3	19

#	ARTICLE	IF	CITATIONS
73	T-Cell Antigen Receptor-alpha Chain Transmembrane Peptides: Correlation between Structure and Function. <i>International Journal of Peptide Research and Therapeutics</i> , 2006, 12, 261-267.	0.9	14
74	Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006, 1763, 879-888.	1.9	35
75	Immunoreceptor Transmembrane Peptides and Their Effect on Natural Killer (NK) Cell Cytotoxicity. <i>Protein and Peptide Letters</i> , 2006, 13, 1017-1024.	0.4	14
76	Resolution of sclerodermatous myocarditis after autologous stem cell transplantation. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1247-1248.	0.5	16
77	Systemic scleroderma: a spatiotemporal clustering. <i>Internal Medicine Journal</i> , 2005, 35, 228-233.	0.5	18
78	Histiocytosis and bone: experience from one major Sydney teaching hospital. <i>Internal Medicine Journal</i> , 2005, 35, 622-625.	0.5	5
79	Proteomics in Rheumatology: A New Direction for Old Diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 67-76.	1.6	19
80	Hydrophobic Transmembrane-Peptide Lipid Conjugations Enhance Membrane Binding and Functional Activity in T-Cells. <i>Bioconjugate Chemistry</i> , 2005, 16, 1556-1563.	1.8	18
81	Chemotherapeutic induced fascial oedema. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 162-163.	0.5	2
82	Advanced refractory polymyositis responding to infliximab. <i>British Journal of Rheumatology</i> , 2005, 44, 562-563.	2.5	42
83	T Cell Antigen Receptor Peptide-Lipid Membrane Interactions Using Surface Plasmon Resonance. <i>Journal of Biological Chemistry</i> , 2004, 279, 54002-54007.	1.6	33
84	Photoactive benzophenone labelled peptide. <i>APLAR Journal of Rheumatology</i> , 2004, 7, 11-12.	0.2	0
85	Transmembrane T-cell receptor peptides inhibit B- and natural killer-cell function. <i>Immunology</i> , 2003, 108, 458-464.	2.0	19
86	Secondary screening for osteoporosis in patients admitted with minimal-trauma fracture to a major teaching hospital. <i>Internal Medicine Journal</i> , 2003, 33, 505-510.	0.5	37
87	Clopidogrel-associated acute arthritis. <i>Internal Medicine Journal</i> , 2003, 33, 618-619.	0.5	20
88	CCR5 Genotyping in an Australian and New Zealand Type 1 Diabetes Cohort. <i>Autoimmunity</i> , 2002, 35, 457-461.	1.2	10
89	Relationship of tumour necrosis factor alpha gene polymorphisms and neuropsychiatric lupus. <i>Lupus</i> , 2002, 11, 114-118.	0.8	10
90	T-Cell Antigen Receptor Peptides Inhibit Signal Transduction within the Membrane Bilayer. <i>Clinical Immunology</i> , 2002, 105, 199-207.	1.4	32

#	ARTICLE	IF	CITATIONS
91	T cell antigen receptor (TCR) transmembrane peptides colocalize with TCR, not lipid rafts, in surface membranes. <i>Cellular Immunology</i> , 2002, 215, 12-19.	1.4	29
92	LETTERS TO THE EDITOR. <i>Australasian Journal of Dermatology</i> , 2002, 43, 226-227.	0.4	15
93	Biophysical studies of a transmembrane peptide derived from the T cell antigen receptor. <i>International Journal of Peptide Research and Therapeutics</i> , 2001, 8, 227-233.	0.1	7
94	Peptide delivery systems. <i>International Journal of Peptide Research and Therapeutics</i> , 2001, 8, 289-294.	0.1	10
95	Biophysical studies of a transmembrane peptide derived from the T cell antigen receptor. <i>International Journal of Peptide Research and Therapeutics</i> , 2001, 8, 227-233.	0.1	6
96	Peptide delivery systems. <i>International Journal of Peptide Research and Therapeutics</i> , 2001, 8, 289-294.	0.1	1
97	Investigation of the $\epsilon$ 1377 polymorphism on the apo-1/fas promoter in systemic lupus erythematosus patients using allele-specific amplification. <i>Pathology</i> , 2000, 32, 126-130.	0.3	25
98	Evaluation of the Apo-1/Fas promoter Mva I polymorphism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, 14-18.	1.4	20
99	Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. <i>British Journal of Rheumatology</i> , 1999, 38, 645-651.	2.5	71
100	A Fas promoter polymorphism at position $\epsilon$ 670 in the enhancer region does not confer susceptibility to Felty's and large granular lymphocyte syndromes. <i>Rheumatology</i> , 1999, 38, 883-886.	0.9	20
101	Familial risk estimation in systemic sclerosis. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 36-41.	0.5	61
102	The Interchain Disulfide Linkage of T-Cell Antigen Receptor- $\epsilon$ 1 and - $\epsilon$ 2 Chains Is a Prerequisite for T-Cell Activation. <i>Cellular Immunology</i> , 1998, 190, 101-111.	1.4	5
103	Charles Bonnet Syndrome in Giant Cell Arteritis. <i>Journal of Clinical Rheumatology</i> , 1998, 4, 144-146.	0.5	1
104	X-Chromosome Inactivation in Monozygotic Twins with Systemic Lupus Erythematosus. <i>Autoimmunity</i> , 1997, 26, 85-93.	1.2	31
105	Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. <i>Molecular Immunology</i> , 1997, 34, 577-582.	1.0	242
106	The use of biologics in the treatment of rheumatoid arthritis (RA). <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 607-607.	0.5	0
107	T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. <i>Nature Medicine</i> , 1997, 3, 84-88.	15.2	113
108	Family and twin studies in systemic lupus erythematosus. <i>Disease Markers</i> , 1997, 13, 93-8.	0.6	48

#	ARTICLE	IF	CITATIONS
109	A family study of allergy: Segregation with HLA but not with T-cell receptor genes. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 712-713.	1.5	14
110	Conformation of the T $\alpha$ -Cell Antigen Receptor $\alpha$ 1 $\beta$ Chain C $\alpha$ D Domain Contributes to V $\beta$ 3 Epitope Recognition by Monoclonal Antibody KJ25. <i>Scandinavian Journal of Immunology</i> , 1996, 43, 140-145.	1.3	3
111	Structural mutations in the constant region of the T-cell antigen receptor (TCR)beta chain and their effect on TCR alpha and beta chain interaction. <i>Immunology</i> , 1996, 88, 524-30.	2.0	11
112	The T cell antigen receptor beta chain interacts with the extracellular domain of CD3 $\beta$ . <i>Immunology and Cell Biology</i> , 1995, 73, 532-536.	1.0	5
113	Hierarchy of T cell antigen receptor assembly. <i>Immunology and Cell Biology</i> , 1995, 73, 544-548.	1.0	13
114	Immunogenetic analysis of 5 families with multicase occurrence of scleroderma and/or related variants. <i>Journal of Rheumatology</i> , 1995, 22, 85-92.	1.0	17
115	The T cell antigen receptor $\alpha$ 1 and $\alpha$ 2 chains interact via distinct regions with CD3 chains. <i>European Journal of Immunology</i> , 1994, 24, 84-92.	1.6	79
116	Renal disease and rheumatic manifestations. <i>Current Opinion in Rheumatology</i> , 1994, 6, 82-84.	2.0	3
117	Role of T $\alpha$ -cell antigen receptors in rheumatic disease. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 205-212.	0.5	1
118	Transmembrane helical interactions: zeta chain dimerization and functional association with the T cell antigen receptor.. <i>EMBO Journal</i> , 1992, 11, 3245-3254.	3.5	96
119	Lymphocyte migration in health and inflammatory rheumatic disease. <i>Seminars in Arthritis and Rheumatism</i> , 1991, 20, 339-352.	1.6	16
120	Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor.. <i>EMBO Journal</i> , 1991, 10, 1643-1651.	3.5	156
121	Arachidonic acid metabolites in normal and autoimmune mice do not influence lymphocyte $\alpha$ high endothelial venule interactions. <i>Immunology and Cell Biology</i> , 1991, 69, 39-46.	1.0	1
122	Identification of a murine monoclonal antibody specific for an allotypic determinant on mouse CD3. <i>European Journal of Immunology</i> , 1991, 21, 1703-1709.	1.6	36
123	Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor. <i>EMBO Journal</i> , 1991, 10, 1643-51.	3.5	53
124	Transmembrane helical interactions and the assembly of the T cell receptor complex. <i>Science</i> , 1990, 249, 274-277.	6.0	223
125	Aberrant Lymphocyte Migration Patterns in Systemic Lupus Erythematosus (MRL/l, MRL/n) Mice are Independent of the Micro-Environment. <i>Autoimmunity</i> , 1990, 7, 139-148.	1.2	2
126	Lymphocyte Migration Patterns in Autoimmune MRL-lpr/lpr Mice: Relationship to Age, Disease Manifestations and Lymphocyte Homing Receptor Expression. <i>Autoimmunity</i> , 1989, 3, 5-15.	1.2	3



#	ARTICLE	IF	CITATIONS
127	Enhanced interferon-gamma (IFN) production by lymph node cells from autoimmune (MRL/1, MRL/n) mice. <i>Clinical and Experimental Immunology</i> , 1989, 76, 301-6.	1.1	29
128	High endothelial venule morphology and function are inducible in germ-free mice: A possible role for interferon- $\beta$ . <i>Cellular Immunology</i> , 1988, 117, 136-151.	1.4	24
129	Anti-Ia monoclonal antibody (10-2.16) inhibits lymphocyte-high endothelial venule (HEV) interaction. <i>Cellular Immunology</i> , 1988, 117, 152-164.	1.4	16
130	Pseudo-avascular necrosis of the hips in a sporadic case of osteopetrosis. <i>Clinical Rheumatology</i> , 1987, 6, 408-411.	1.0	1
131	CURRENT CONCEPTS IN THE ETIOPATHOGENESIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). <i>Australian and New Zealand Journal of Medicine</i> , 1986, 16, 729-743.	0.5	6